WallStreetZenWallStreetZen

NASDAQ: ARGX
Argenx Se Stock

$373.29+2.34 (+0.63%)
Updated Feb 6, 2023
ARGX Price
$373.29
Fair Value Price
$399.42
Market Cap
$20.55B
52 Week Low
$256.44
52 Week High
$407.93
P/E
-21.24x
P/B
6.85x
P/S
652.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$29.79M
Earnings
-$955.12M
Gross Margin
78.4%
Operating Margin
-3,122.06%
Profit Margin
-3,077%
Debt to Equity
0.09
Operating Cash Flow
-$910M
Beta
0.78
Next Earnings
Mar 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ARGX Overview

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ARGX ($373.29) is undervalued by 6.54% relative to our estimate of its Fair Value price of $399.42 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ARGX ($373.29) is not significantly undervalued (6.54%) relative to our estimate of its Fair Value price of $399.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARGX due diligence checks available for Premium users.

Be the first to know about important ARGX news, forecast changes, insider trades & much more!

ARGX News

Valuation

ARGX fair value

Fair Value of ARGX stock based on Discounted Cash Flow (DCF)
Price
$373.29
Fair Value
$399.42
Undervalued by
6.54%
ARGX ($373.29) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARGX ($373.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ARGX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-21.24x
Industry
11.5x
Market
14.99x

ARGX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.85x
Industry
5.06x
ARGX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ARGX's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
ARGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ARGX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.4B
Liabilities
$293.7M
Debt to equity
0.09
ARGX's short-term assets ($2.96B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARGX's short-term assets ($2.96B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ARGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
ARGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ARGX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ARGX$20.55B+0.63%-21.24x6.85x
BMRN$20.85B-0.02%249.29x4.56x
INCY$18.77B+0.90%21.30x4.44x
RPRX$23.24B-1.77%33.57x2.23x
SGEN$25.25B-1.45%-39.42x8.95x

Argenx Se Stock FAQ

What is Argenx Se's quote symbol?

NASDAQ: ARGX) Argenx Se trades on the NASDAQ under the ticker symbol ARGX. Argenx Se stock quotes can also be displayed as NASDAQ: ARGX.

If you're new to stock investing, here's how to buy Argenx Se stock.

What is the 52 week high and low for Argenx Se (NASDAQ: ARGX)?

(NASDAQ: ARGX) Argenx Se's 52-week high was $407.93, and its 52-week low was $256.44. It is currently -8.49% from its 52-week high and 45.57% from its 52-week low.

How much is Argenx Se stock worth today?

(NASDAQ: ARGX) Argenx Se currently has 55,061,502 outstanding shares. With Argenx Se stock trading at $373.29 per share, the total value of Argenx Se stock (market capitalization) is $20.55B.

Argenx Se stock was originally listed at a price of $23.00 in May 18, 2017. If you had invested in Argenx Se stock at $23.00, your return over the last 5 years would have been 1,523%, for an annualized return of 74.61% (not including any dividends or dividend reinvestments).

How much is Argenx Se's stock price per share?

(NASDAQ: ARGX) Argenx Se stock price per share is $373.29 today (as of Feb 6, 2023).

What is Argenx Se's Market Cap?

(NASDAQ: ARGX) Argenx Se's market cap is $20.55B, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Argenx Se's market cap is calculated by multiplying ARGX's current stock price of $373.29 by ARGX's total outstanding shares of 55,061,502.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.